Spruce Street Capital LP Buys Shares of 5,352,198 InflaRx N.V. $IFRX

Spruce Street Capital LP acquired a new stake in InflaRx N.V. (NASDAQ:IFRX) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 5,352,198 shares of the company’s stock, valued at approximately $11,988,924. InflaRx makes up approximately 0.0% of Spruce Street Capital LP’s portfolio, making the stock its 13th biggest holding. Spruce Street Capital LP owned about 3.63% of InflaRx as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. Sanctuary Advisors LLC bought a new position in InflaRx in the 2nd quarter valued at approximately $25,000. DCF Advisers LLC purchased a new stake in shares of InflaRx in the 2nd quarter worth $512,000. ADAR1 Capital Management LLC purchased a new stake in InflaRx during the first quarter valued at approximately $142,000. XTX Topco Ltd bought a new position in shares of InflaRx during the 4th quarter worth approximately $135,000. Finally, Suvretta Capital Management LLC lifted its holdings in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

InflaRx Price Performance

Shares of IFRX stock traded up $0.01 during mid-day trading on Friday, hitting $2.28. The stock had a trading volume of 349,887 shares, compared to its average volume of 1,161,796. InflaRx N.V. has a fifty-two week low of $0.80 and a fifty-two week high of $2.95. The firm has a market cap of $336.00 million, a PE ratio of -3.93 and a beta of 2.48. The company’s 50-day simple moving average is $1.98 and its 200-day simple moving average is $1.65.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, analysts expect that InflaRx N.V. will post -0.31 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Zacks Research cut InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Wall Street Zen upgraded shares of InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Raymond James Financial upgraded shares of InflaRx from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Finally, HC Wainwright increased their target price on InflaRx from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, InflaRx has an average rating of “Moderate Buy” and an average target price of $7.33.

About InflaRx

InflaRx N.V. is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement?1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX?1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro?inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high?unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.